Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Iovance Biotherapeutics (IOVA) over the last 6 years, with Sep 2025 value amounting to -$4.4 million.

  • Iovance Biotherapeutics' Change in Account Payables fell 130.43% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 177.90%. This contributed to the annual value of -$7.8 million for FY2024, which is 262.41% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Change in Account Payables of -$4.4 million as of Q3 2025, which was down 591.94% from $893,000 recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Change in Account Payables high stood at $14.4 million for Q3 2024, and its period low was -$10.4 million during Q2 2024.
  • In the last 3 years, Iovance Biotherapeutics' Change in Account Payables had a median value of $146,000 in 2023 and averaged -$405,545.
  • The largest annual percentage gain for Iovance Biotherapeutics' Change in Account Payables in the last 5 years was 247.82% (2024), contrasted with its biggest fall of 7,216.44% (2024).
  • Over the past 3 years, Iovance Biotherapeutics' Change in Account Payables (Quarterly) stood at $11.4 million in 2023, then crashed by 153.16% to -$6.1 million in 2024, then plummeted by 130.43% to -$4.4 million in 2025.
  • Its Change in Account Payables stands at -$4.4 million for Q3 2025, versus $893,000 for Q2 2025 and $2.1 million for Q1 2025.